GlassScriptPhysician profile
James Jeffrey Steen
NPI 1487275145
$585.42
in general payments reported to CMS, 2019-2025
11 companies · $190 in 2025
The $190 reported for 2025 was more than what 75% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $122 · 2024: $274 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $189.66 | 2025 | Barostim Neo System |
| Novo Nordisk INC | $95.51 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $53.68 | 2023 | Rexulti |
| Astellas Pharma US INC | $53.06 | 2023-2024 | Veozah |
| Lilly USA, LLC | $52.09 | 2024 | Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $42.93 | 2024 | Airsupra |
| Pfizer INC. | $35.63 | 2023-2024 | |
| Exact Sciences Corporation | $18.88 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $16.93 | 2024 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.65 | 2024 | Xifaxan, Trulance |
| La Jolla Pharmaceutical Company | $13.40 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Steen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.